Morinaga Sei, Zhao Ming, Mizuta Kohei, Kang Byung Mo, Bouvet Michael, Yamamoto Norio, Hayashi Katsuhiro, Kimura Hiroaki, Miwa Shinji, Igarashi Kentaro, Higuchi Takashi, Tsuchiya Hiroyuki, Demura Satoru, Hoffman Robert M
AntiCancer Inc., San Diego, CA, U.S.A.
Department of Surgery, University of California, San Diego, CA, U.S.A.
In Vivo. 2025 Mar-Apr;39(2):640-647. doi: 10.21873/invivo.13869.
BACKGROUND/AIM: A1-R (A1-R) expresses green fluorescent protein (GFP) and has the ability to selectively target and inhibit all major cancer types in murine models without persistently infecting healthy tissue. A1-R is being developed for tumor targeting by oral administration. The aim of the present study was to demonstrate real-time imaging of orally-administered A1-R in a fibrosarcoma nude-mouse model and to visualize its trafficking through the gastrointestinal system to the tumor and normal organs.
A1-R-GFP (3.3×10 colony-forming units/ml) was administered orally to HT1080 human fibrosarcoma nude-mouse models which were fasted the day before administration. Fluorescence images of A1-R-GFP inside the gastrointestinal tract at 0, 2 and 4 hours after oral gavage were captured. The number of colonies of A1-R-GFP in tumors and liver were determined at 4 hours, and on days 1, 3 and 4 by growth from homogenized tumor and liver tissue on agar plates.
The trafficking of A1-R-GFP through the murine gastrointestinal tract post-gavage was monitored in real-time GFP fluorescence imaging. Bacteria, initially observed in the stomach, migrated to the small intestine and the colon and subsequently to the subcutaneously-implanted fibrosarcoma. A1-R-GFP proliferated in the tumors over time. In contrast, A1-R-GFP in the liver diminished over time.
The present study showed the pathway of orally administered A1-R-GFP in the gastrointestinal system and to the tumor and liver. A1-R selectively proliferated continuously in tumors and was cleared from the liver. These results are critical for future clinical trials of orally-administered A1-R-GFP.
背景/目的:A1 - R表达绿色荧光蛋白(GFP),在小鼠模型中能够选择性靶向并抑制所有主要癌症类型,且不会持续感染健康组织。目前正在研发通过口服给药实现肿瘤靶向的A1 - R。本研究的目的是在纤维肉瘤裸鼠模型中展示口服A1 - R的实时成像,并观察其通过胃肠道系统向肿瘤和正常器官的转运情况。
将A1 - R - GFP(3.3×10集落形成单位/毫升)口服给予HT1080人纤维肉瘤裸鼠模型,给药前一天禁食。在灌胃后0、2和4小时采集胃肠道内A1 - R - GFP的荧光图像。在4小时以及第1、3和4天,通过将肿瘤和肝脏组织匀浆接种于琼脂平板上培养,测定肿瘤和肝脏中A1 - R - GFP的集落数。
通过实时GFP荧光成像监测了灌胃后A1 - R - GFP在小鼠胃肠道中的转运情况。最初在胃中观察到的细菌迁移至小肠和结肠,随后到达皮下植入的纤维肉瘤。随着时间推移,A1 - R - GFP在肿瘤中增殖。相比之下,肝脏中的A1 - R - GFP随时间减少。
本研究展示了口服A1 - R - GFP在胃肠道系统以及向肿瘤和肝脏的转运途径。A1 - R在肿瘤中选择性持续增殖,并从肝脏中清除。这些结果对于口服A1 - R - GFP未来的临床试验至关重要。